NCT00678275View on ClinicalTrials.gov

Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia

PHASE3CompletedINTERVENTIONAL
Enrollment

161

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

February 28, 2014

Study Completion Date

March 31, 2015

Conditions
Acute Myeloid LeukemiaAcute Lymphoblastic Leukemia
Interventions
DRUG

ATG FRESENIUS (Anti-Lymphocyte-Globulin)

conditioning regimen with ATG: ATG FRESENIUS dosing: 10mg/kg/day, (day -3, -2,-1) when randomised Arm A

DRUG

ATG FRESENIUS (Anti-Lymphocyte-Globulin)

conditioning regimen WITHOUT ATG when randomised Arm B

Trial Locations (1)

20246

University Medical Center Hamburg-Eppendorf, Hamburg

All Listed Sponsors
lead

Universitätsklinikum Hamburg-Eppendorf

OTHER

NCT00678275 - Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia | Biotech Hunter | Biotech Hunter